New analyses presented at CHEST bring a differing perspective to the debate surrounding adaptive servo ventilation device therapy in patients with heart failure with reduced ejection fraction and central sleep apnea, reports MD Magazine.

In assessing the sole treatment of CSA with SRV in patients with both the sleeping disorder and HFrEF, Saraf and his team pulled from a pre-established population of patients at the university’s Sleep Heart Program. They compared mortality between ASV-treated HFrEF-CSA patients, and patients who previously did not accept positive airway pressure (PAP) therapy.

Get the full story at www.mdmag.com

At the beginning, use your PAP machine for short stints during the day while you read or watch TV, reports Harvard Health.

Schedule a regular time to clean your equipment. Clean your mask, tubing, and headgear once a week, ideally on the same day and time so you don’t forget.

Get the full story at www.health.harvard.edu

A US survey, conducted by The Harris Poll and sponsored by Jazz Pharmaceuticals, asked more than 300 sleep apnea patients and more than 300 partners of people living with sleep apnea about key topics connected to their experiences with excessive daytime sleepiness.

The survey found that than one-third (36%) of patients said their excessive daytime sleepiness has caused them to miss out on activities or events, avoid social situations, or give up activities. In addition, 17% of patients said excessive daytime sleepiness has led to problems at work (such as missing a deadline or meeting, being disciplined at work, losing/leaving a job, making a special arrangement, or missing out on opportunities like a raise or promotion), and 14% have fallen asleep at the wheel of a motorized vehicle (either stopped at a light/sign or while driving) in the last 12 months.

Nearly half of partners surveyed (45%) felt their significant other’s excessive daytime sleepiness negatively impacted their relationships, and 32% of partners reported having avoided social situations or missed activities/events because of their partner’s excessive daytime sleepiness.

“The kind of

ResApp Health Limited, a Brisbane, Australia-based digital health company developing smartphone applications for the diagnosis and management of respiratory disease, reports positive results from its prospective, double-blind obstructive sleep apnea (OSA) clinical study. Analysis confirmed that ResApp’s machine-learning algorithms were able to accurately identify OSA from a patient’s overnight breathing and snoring sounds recorded using only a smartphone placed on a bedside table. The company is working with Drs Philip Currie and Ivan Ling of Cardio Respiratory Sleep (CRS), who recruited patients at Hollywood Private Hospital and The Park Private Hospital in Perth, Australia.

Data from 582 adult patients was analyzed, of which 62% were male. The mean age of patients was 53 years (range 18-94) with a mean apnea hypopnea index (AHI) of 26/h (range 0-143).

ResApp’s algorithms achieved 84% sensitivity and 83% specificity for identifying patients with an AHI greater than or equal to 5/h (patients with mild, moderate, or severe OSA) compared to simultaneous gold standard in-laboratory polysomnography scored using the current 2012 American Academy of Sleep Medicine (AASM) scoring criteria. The area under the receiver operating

A new study authored by Jordan Stern, MD, founder and director of BlueSleep Sleep Apnea and Snoring Center based in New York, NY and Darlyne Johnson, MD, a partner at South Shore Women’s Health in Boston, MA, concluded that the BedJet climate comfort system for beds is a highly effective, non-hormonal treatment for women suffering from menopausal sleep disturbance.

The study, titled The Efficacy of the BedJet Climate System for Peri-Menopausal Night Sweat and Hot Flash Symptoms and Corresponding Impact on Sleep, will be published as an abstract in the December issue of the scientific journal Menopause: The Journal of The North American Menopause Society. Stern and Johnson presented the results during the poster session at the North American Menopause Society Conference in San Diego on October 4.

The study evaluated the effectiveness of the BedJet System in a population of 46 peri-menopausal and menopausal women experiencing hot flashes, night sweats and sleep disturbances. Effectiveness was measured using validated sleep, menopausal symptom and quality of life surveys and subjects used the BedJet System for a period of at least

Inspire Medical Systems Inc, a medical technology company that makes an implantable therapy for obstructive sleep apnea (OSA) and is focused on the development and commercialization of minimally invasive solutions for patients with the sleep disorder, has successfully implanted a new sensing lead (model number 4340) in Europe. Dr Joachim Maurer, University Hospital, Mannheim, Germany, who has now overseen 80 Inspire therapy cases, completed the implant. Maurer is an ear, nose, and throat (ENT) surgeon and head of the sleep disorders center.

The sensing lead monitors a patient’s respiratory pattern as the implanted Inspire system delivers stimulation to the upper airway in order to prevent obstructions during sleep. The new 4340 sensing lead has a smaller profile, including a reduction in diameter of 49% as compared to the prior design. The new design also incorporates several features to enhance the ease of implant and reduce surgical time for an ENT surgeon.

“We are pleased to have successfully completed the first case in Europe incorporating the new sensing lead for Inspire therapy,” says Maurer, in a release. “The improved features of